F M Investments LLC Acquires New Stake in NeoGenomics, Inc. (NASDAQ:NEO)

F M Investments LLC acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 126,495 shares of the medical research company's stock, valued at approximately $2,085,000. F M Investments LLC owned about 0.10% of NeoGenomics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in NEO. SBI Securities Co. Ltd. purchased a new position in NeoGenomics during the 4th quarter valued at about $26,000. Versant Capital Management Inc boosted its position in shares of NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock valued at $30,000 after acquiring an additional 1,142 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of NeoGenomics by 203.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock worth $70,000 after purchasing an additional 2,787 shares in the last quarter. Blue Trust Inc. raised its stake in NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock valued at $73,000 after purchasing an additional 1,103 shares in the last quarter. Finally, KBC Group NV lifted its position in NeoGenomics by 44.7% during the fourth quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock valued at $108,000 after purchasing an additional 2,027 shares during the last quarter. Institutional investors own 98.50% of the company's stock.

NeoGenomics Trading Down 0.8 %

NEO stock traded down $0.08 during trading on Thursday, reaching $9.48. The company had a trading volume of 616,811 shares, compared to its average volume of 948,014. The business has a 50 day moving average of $10.34 and a 200 day moving average of $13.68. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The company has a market cap of $1.22 billion, a P/E ratio of -15.34 and a beta of 1.41. NeoGenomics, Inc. has a 52 week low of $8.05 and a 52 week high of $19.12.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $172.00 million during the quarter, compared to the consensus estimate of $173.40 million. As a group, sell-side analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on NEO. Needham & Company LLC lowered their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Bank of America decreased their price objective on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, February 19th. Benchmark cut shares of NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. The Goldman Sachs Group decreased their target price on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Finally, Piper Sandler reduced their price objective on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.60.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.